An interventional study of Robotic Rehabilitation with PABLO® and Standard Gym Rehabilitation in Tetraplegia/Tetraparesis, Rehabilitation Treatment and Gaining Skeletal Muscle Mass and Strength, sponsored by IRCCS Sacro Cuore Don Calabria di Negrar. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by IRCCS Sacro Cuore Don Calabria di Negrar · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to evaluate the efficacy of upper-limb robotic rehabilitation training (PABLO®) for recovering muscle strength in the scapulohumeral region and the proximal upper limb-compared to standard rehabilitation treatment alone-in male and female patients aged 18 to 80 years with tetraplegia/tetraparesis due to spinal cord injury of various etiologies (traumatic, ischemic, infectious, etc.) in the subacute phase.
The rehabilitation protocol includes:
- 2 weeks of standard upper limb gym rehabilitation treatment;
Randomization of patients into two treatment groups (lasting 3 weeks):
For the evaluation of neurological assessment of motor and sensory functions will be used the American Spinal Injury Association (ASIA) Impairment Scale.
Specifically, the assessment of muscle strength of proximal muscles of the upper limb and the scapulohumeral region will be used the Medical Research Council (MRC) scale.
The enrollment evaluation (V0) consists of a physiatric examination, including an assessment of motor function and muscle strength in the scapulohumeral region and the proximal portions of the upper limbs, as well as any sensory deficits in the upper limbs, followed by determination of the neurological level of injury and classification according to the ASIA Impairment Scale. After two to four weeks of hospitalization, during which the patient undergoes standard rehabilitation, the examiner reevaluates the patient (V1).
After two weeks of standard upper-limb rehabilitation, the patient undergoes a further clinical reevaluation (V2) and is subsequently randomized into two treatment groups: Arm A (experimental arm) or Arm B (standard control arm). At the end of this training period, the patient will be re-evaluated (V3) by the same examiner who conducted the V1 visit and who will be blinded to the rehabilitation treatment received by the patient (the patient will be asked not to disclose the type of rehabilitation performed).
224 studies on the registry are indexed under Quadriplegia; 77 are open to participants now.
This study's planned enrollment of 24 is above the median of 15 across 195 interventional studies indexed under Quadriplegia.
Browse Quadriplegia studies →IRCCS Sacro Cuore Don Calabria di Negrar is the lead sponsor of 38 studies on the registry; 22 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
PRIMARY
SECONDARY
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Robotic Rehabilitation with PABLO®
Procedure: Standard Gym Rehabilitation
3 weeks of robotic rehabilitation treatment with PABLO®, consisting of 15 rehabilitation sessions, each lasting 1 hour, for the upper limbs, focused on restoring strength and motor function. Treatments involve one-dimensional (lateral-lateral or anteroposterior) and two-dimensional active mobilization of the upper extremities using the PABLO® Multiboard, a device that secures the hand and wrist with a handle and allows for flexion and extension movements of the elbow and shoulder.
3 weeks of standard rehabilitation treatment, consisting of 15 rehabilitation sessions in the gym (5 per week for 3 consecutive weeks), each lasting 1 hour. Treatments are designed to maintain or restore range of motion in the shoulder joint through passive, active-assisted, and active mobilization exercises guided by the physical therapist, strength training of the proximal muscles of the upper limb, electrostimulation of the proximal muscles of the upper limb and use of physical therapies for analgesic and anti-inflammatory purposes.
Neurological assessment of motor function and sensation
Neurological assessment of motor function and sensation using the American Spinal Injury Association (ASIA) Impairment Scale. Assessment of muscle strength using the Medical Research Council (MRC) scale for the proximal muscles of the upper limb and the scapulohumeral region (flexion-extension, abduction/adduction, internal and external rotation of the shoulder, and flexion-extension of the elbow), administered both before and after treatment.
Time frame: From enrollment (Visit 0) to Visit 3 (7-9 weeks after Visit 0)
Passive Range of Motion (pROM)
Passive Range of Motion (pROM) at the scapulohumeral joint across various planes of motion (flexion-extension, abduction/adduction, internal and external rotation of the shoulder, and flexion-extension of the elbow), measured both pre- and post-treatment
Time frame: From enrollment (Visit 0) to Visit 3 (7-9 weeks after Visit 0)
Numerical Rating Scale (NRS)
Numerical Rating Scale (NRS) for assessing shoulder pain, recorded at all visits, both pre- and post-treatment;
Time frame: From Visit 1 (2-4 weeks after Visit 0) to Visit 3 (7-9 weeks after Visit 0)
Spinal Cord Independence Measure (SCIM-III) scale
Spinal Cord Independence Measure (SCIM-III) scale, measured both pre- and post-treatment
Time frame: From enrollment (Visit 0) to Visit 3 (7-9 weeks after Visit 0)
number of sessions required before beginning 2D exercises
number of sessions required before beginning 2D exercises
Time frame: At Visit 2 (4-6 weeks after Visit 0) and Visit 3 (7-9 after Visit 0)
Wheelchair Skills Test Italian Version 4.3 Powered Mobility Devices (WST-I 4.3 PMD)
Wheelchair Skills Test Italian Version 4.3 Powered Mobility Devices (WST-I 4.3 PMD), measured pre- and post-treatment
Time frame: At Visit 2 (4-6 weeks after Visit 0) and Visit 3 (7-9 after Visit 0)
Modified Physical Therapy Patient Satisfaction Questionnaire (PTPSQ-1 mod)
Modified Physical Therapy Patient Satisfaction Questionnaire (PTPSQ-1 mod), completed during the final visit
Time frame: At Visit 3 (7-9 weeks after Visit 0)
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Oct 2027, 42 months after the start.
Of 77 non-industry interventional studies with no phase under Quadriplegia, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 309. This study's planned 42 months is below that.
Counting every sponsor, half of 97 studies reached it within 41 months; a quarter within 16 and three quarters within 309.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Sacro Cuore Don Calabria di Negrar